InvestorsObserver is giving Concert Pharmaceuticals Inc (CNCE) an Analyst Rating Rank of 80, meaning CNCE is ranked higher by analysts than 80% of stocks. The average projection by analysts for CNCE is $23.75 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Concert Pharmaceuticals Inc Stock Today?
Concert Pharmaceuticals Inc (CNCE) stock has fallen -4.69% while the S&P 500 has risen 0.67% as of 2:25 PM on Thursday, Sep 24. CNCE has fallen -$0.46 from the previous closing price of $9.81 on volume of 146,996 shares. Over the past year the S&P 500 has gained 9.17% while CNCE has fallen -11.29%. CNCE lost -$2.70 per share the over the last 12 months.